Cellular and Gene Therapy for Major Histocompatibility Complex Class II Deficiency

Matheux, Franck; Villard, Jean

doi:10.1152/nips.01462.2003

Scientific article

Review

English

Cellular and Gene Therapy for Major Histocompatibility Complex Class II Deficiency

ContributorsMatheux, Franck; Villard, Jean

Published inNews in physiological sciences, vol. 19, no. 3, p. 154-158

Publication date2004-06

Abstract

Major histocompatibility complex (MHC) class II deficiency is a primary immunodeficiency. Lentiviral vectors are used for gene therapy in a mouse model of this disease. In addition, by a direct genetic correction approach, a diagnostic test to determine which of the four MHC II genes is defective in new MHC II-deficiency patients has been optimized.

Keywords

Animals
Genetic Therapy
Histocompatibility Antigens Class II / genetics
Humans
Severe Combined Immunodeficiency / genetics
Severe Combined Immunodeficiency / therapy

Affiliation entities

Research groups

Transplantation immunologie et osteoimmunologie (561)

Citation (ISO format)

MATHEUX, Franck, VILLARD, Jean. Cellular and Gene Therapy for Major Histocompatibility Complex Class II Deficiency. In: News in physiological sciences, 2004, vol. 19, n° 3, p. 154–158. doi: 10.1152/nips.01462.2003

Article (Published version)

Identifiers

PID : unige:167045
DOI : 10.1152/nips.01462.2003
PMID : 15143213

Additional URL for this publicationhttps://www.physiology.org/doi/10.1152/nips.01462.2003

Journal ISSN0886-1714

111views

0downloads

Creation22/09/2022 13:29:00

First validation22/09/2022 13:29:00

Update14/11/2024 14:49:28

Status update14/11/2024 14:49:28

Last indexation14/11/2024 14:52:57

Archive ouverte UNIGE

Cellular and Gene Therapy for Major Histocompatibility Complex Class II Deficiency

Technical informations